Drug Trial Radar · NCT00620854
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Feb 2008
Primary completion
Apr 2008
Study completion Apr 2008
Sponsor
- Lead sponsor
- Tarsa Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 22, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- Female only, from 45 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
Conditions
- Osteoporosis
Interventions
Recombinant Salmon Calcitonin (rsCT)Drug
Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
Oral TabletDrug
0.15 mgs recombinant salmon calcitonin, single oral dose
Oral TabletDrug
0.2mgs recombinant salmon calcitonin, single oral tablet
Nasal SprayDrug
200 IU recombinant salmon calcitonin, single intranasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma C-terminal Telopeptide of Type I Collagen (CTx-1)(% Change From Baseline)Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, and 24 hours (Fortical): 0, 2, 3, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 10, 12, 24 hours rsCTA and rsCTB
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bio-Kinetic Clinical Applications, Inc.
Springfield, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.